A practical reference on reversed-phase HPLC: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Independent verification is central to quality control because the compound is not produced under pharmaceutical manufacturing standards. Third-party laboratories can measure purity, identity, residual solvents, and microbial contamination, though the scope of testing varies between services. Reported analyses of vendor samples have shown batch-to-batch variation in peptide content and the presence of truncated or oxidized species. How much of this variation reflects synthesis conditions versus storage and shipping is not well characterized. No harmonized reference standard exists for the material as sold.
Handling guidance for melanotan II follows general practice for small synthetic peptides rather than a product-specific monograph. Lyophilized powder is typically kept at minus twenty degrees Celsius or colder, protected from light and moisture, because warmth and humidity accelerate degradation. Once reconstituted, solutions are usually refrigerated and used within a short window, as hydrolysis and microbial growth both become concerns. Repeated freeze-thaw cycles are generally avoided. These conventions come from laboratory peptide chemistry and not from formal stability studies on this specific compound.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
In the absence of an effective enantiomeric environment (precursor, chiral catalyst, or kinetic resolution), separation of a racemic mixture into its enantiomeric components is impossible, although certain racemic mixtures spontaneously crystallize in the form of a racemic conglomerate, in which crystals of the enantiomers are physically segregated and may be separated mechanically. However, most racemates form crystals containing both enantiomers in a 1:1 ratio. In his pioneering work, Louis Pasteur was able to isolate the isomers of sodium ammonium tartrate because the individual enantiomers crystallize separately from solution. To be sure, equal amounts of the enantiomorphic crystals are produced, but the two kinds of crystals can be separated with tweezers. This behavior is unusual. A less common method is by enantiomer self-disproportionation. The second strategy is asymmetric synthesis: the use of various techniques to prepare the desired compound in high enantiomeric excess. Techniques encompassed include the use of chiral starting materials (chiral pool synthesis), the use of chiral auxiliaries and chiral catalysts, and the application of asymmetric induction. The use of enzymes (biocatalysis) may also produce the desired compound. A third strategy is enantioconvergent synthesis, the synthesis of one enantiomer from a racemic precursor, utilizing both enantiomers. By making use of a chiral catalyst, both enantiomers of the reactant result in a single enantiomer of product.
On February 11, 2011, EPA determined that perchlorate meets the Safe Drinking Water Act criteria for regulation as a contaminant. The agency found that perchlorate may have an adverse effect on the health of persons and is known to occur in public water systems with a frequency and at levels that it presents a public health concern. Since then EPA has continued to determine what level of contamination is appropriate. EPA prepared extensive responses to submitted public comments. In 2016, the Natural Resources Defense Council (NRDC) filed a lawsuit to accelerate EPA's regulation of perchlorate. In 2019, EPA proposed a Maximum Contaminant Level of 0.056 mg/L for public water systems. On June 18, 2020, EPA announced that it was withdrawing its 2011 regulatory determination and its 2019 proposal, stating that it had taken "proactive steps" with state and local governments to address perchlorate contamination. In September 2020 NRDC filed suit against EPA for its failure to regulate perchlorate, and stated that 26 million people may be affected by perchlorate in their drinking water. On March 31, 2022, the EPA announced that a review confirmed its 2020 decision. Following the NRDC lawsuit, in 2023 the US Court of Appeals for the DC Circuit ordered EPA to develop a perchlorate standard for public water systems. EPA published a proposed rule for perchlorate on January 6, 2026. The court order requires the agency to issue a final rule in 2027.
==== Hematology ==== There is not enough evidence to support the routine use of tranexamic acid to prevent bleeding in people with blood cancers. However, several trials are currently assessing this use of tranexamic acid. For people with inherited bleeding disorders (e.g. von Willebrand's disease), tranexamic acid is often given. It has also been recommended for people with acquired bleeding disorders (e.g., directly acting oral anticoagulants (DOACs)) to treat serious bleeding.
==== Double-derivatization methods ==== Either the enantiomer of the substrate is derivatized with two enantiomers of the CDA or both enantiomers of the substrate are derivatized with one enantiomer of the CDA. Two diastereomers form in both cases and the chemical shifts of their nuclei are evaluated to assign the configuration of the substrate.
Most players accepted the provisional suspensions immediately; Dustin Fletcher and Jobe Watson both participated in the 2014 International Rules Series test match on 22 November before beginning their suspensions; Alwyn Davey and Leroy Jetta, neither of whom was on the Essendon list any longer, both opted to play the 2014/15 Northern Territory Football League season (which runs over the Australian summer), and did not begin their provisional suspensions until February 2015. After the tribunal hearings were complete, it was announced that a final decision was expected in late March. This meant that the thirty-four players, including seventeen still at Essendon, would be under provisional suspension during the 2015 NAB Challenge pre-season matches. All twenty-five Essendon players who were at the club during the supplements program received permission to miss the series, including eight players who were not facing charges but were permitted to stand aside to protect their teammates' anonymity; of those eight players, four elected to play. Essendon was given permission to field VFL-listed players from its reserves team, and to sign players from state leagues to temporary contracts to serve as top-up players during the NAB Challenge. On 31 March, the week before the opening of the 2015 AFL season, the tribunal announced that it had found the 34 players not guilty. The tribunal confirmed that Thymosin beta-4 was a banned substance during the program, but that it was not comfortably satisfied that the players had been administered the substance.
Sources: en.wikipedia.org
Depressants are psychoactive drugs that temporarily diminish the function or activity of a specific part of the body or mind. Colloquially, depressants are known as "downers", and users generally take them to feel more relaxed and less tense. Examples of these kinds of effects may include anxiolysis, sedation, and hypotension. Depressants are widely used throughout the world as prescription medicines and as illicit substances. When these are used, effects may include anxiolysis (reduction of anxiety), analgesia (pain relief), sedation, somnolence, cognitive/memory impairment, dissociation, muscle relaxation, lowered blood pressure/heart rate, respiratory depression, anesthesia, and anticonvulsant effects. Depressants exert their effects through a number of different pharmacological mechanisms, the most prominent of which include potentiation of GABA or opioid activity, and inhibition of adrenergic, histamine or acetylcholine activity. Some are also capable of inducing feelings of euphoria. The most widely used depressant by far is alcohol (i.e. ethanol). Stimulants or "uppers", such as amphetamines or cocaine, which increase mental or physical function, have an opposite effect to depressants. Depressants, in particular alcohol, can precipitate psychosis. A 2019 systematic review and meta-analysis by Murrie et al. found that the rate of transition from opioid, alcohol and sedative induced psychosis to schizophrenia was 12%, 10% and 9% respectively.
=== Styrene-butane co-polymers === Styrene-butane co-polymers can be produced with a low butene content. Styrene-butane co-polymers include PS-I and SBC (see below), both co-polymers are impact resistant. PS-I is prepared by graft co-polymerization, SBC by anionic block co-polymerization, which makes it transparent in case of appropriate block size. If styrene-butane co-polymer has a high butylene content, styrene-butadiene rubber (SBR) is formed. The impact strength of styrene-butadiene co-polymers is based on phase separation, polystyrene and poly-butane are not soluble in each other (see Flory–Huggins solution theory). Co-polymerization creates a boundary layer without complete mixing. The butadiene fractions (the "rubber phase") assemble to form particles embedded in a polystyrene matrix. A decisive factor for the improved impact strength of styrene-butadiene copolymers is their higher absorption capacity for deformation work. Without applied force, the rubber phase initially behaves like a filler. Under tensile stress, crazes (microcracks) are formed, which spread to the rubber particles. The energy of the propagating crack is then transferred to the rubber particles along its path. A large number of cracks give the originally rigid material a laminated structure. The formation of each lamella contributes to the consumption of energy and thus to an increase in elongation at break. Polystyrene homo-polymers deform when a force is applied until they break.
It results from the slowing of peristalsis in the gut and is a reason dihydrocodeine, ethylmorphine, codeine, opium preparations, and morphine are used to stop diarrhoea and combat irritable bowel syndrome (IBS) in its diarrhoeal and cyclical forms as well as other conditions causing hypermotility or intestinal cramping. Opium/opioid preparations are used often as a last resort where pain is severe and the bowels are organically loose. It is generally better to treat IBS with a non psycho-tropic opioid such as loperamide hydrochloride which stays contained in the bowel, thereby not causing drowsy effects and allowing many people to work using machines etc. For IBS, hyoscine butylbromide (Buscopan in the UK) and mebeverine hydrochloride (Colofac) can be effective with or without an opium related compound.
=== Volatile compounds === Volatile compounds of green coffee beans include short-chain fatty acids, aldehydes, and nitrogen-containing aromatic molecules, such as derivatives of pyrazines (green-herbaceous-earthy odor). When green coffee beans are roasted, other molecules with the typical pleasant aroma of coffee are generated, which are not present in fresh green coffee. During roasting, the major part of the unpleasant-tasting volatile compounds are neutralized.
Sources: en.wikipedia.org
=== Reactive oxygen species generation === Alloxan (C4H2N2O4) readily undergoes redox cycling with its one-electron (C4H3N2O4• semiquinone) and two-electron (dialuric acid, C4H4N2O4) reduction products. In the presence of intracellular reductants such as glutathione (or other thiols), this leads to the generation of toxic reactive oxygen species (ROS) via the interaction of alloxan reduction products with molecular oxygen and related species:
Polymyxins are antibiotics. Polymyxins B and E (also known as colistin) are used in the treatment of Gram-negative bacterial infections. They work mostly by breaking up the bacterial cell membrane. They are part of a broader class of molecules called nonribosomal peptides. They are produced in nature by Gram-positive bacteria such as Paenibacillus polymyxa.
== RF value, solutes, and solvents == The retardation factor (RF) may be defined as the ratio of the distance travelled by the solute to the distance travelled by the solvent. It is used in chromatography to quantify the amount of retardation of a sample in a stationary phase relative to a mobile phase. RF values are usually expressed as a fraction of two decimal places.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
The lyophilized powder is generally held at minus twenty degrees Celsius or below, away from light and moisture. Reconstituted solutions are typically refrigerated and used quickly. These practices derive from general peptide handling rather than a formal stability study.